MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Purchases $46,750.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 25,000 shares of MAIA Biotechnology stock in a transaction dated Friday, December 13th. The shares were purchased at an average cost of $1.87 per share, for a total transaction of $46,750.00. Following the completion of the transaction, the director now owns 1,130,060 shares of the company’s stock, valued at approximately $2,113,212.20. This represents a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

MAIA Biotechnology Trading Down 0.5 %

MAIA stock traded down $0.01 during trading hours on Friday, reaching $2.00. The stock had a trading volume of 70,324 shares, compared to its average volume of 273,036. MAIA Biotechnology, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $5.99.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.21. On average, research analysts expect that MAIA Biotechnology, Inc. will post -1.3 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of MAIA Biotechnology in the third quarter valued at $31,000. Ground Swell Capital LLC bought a new position in MAIA Biotechnology during the 2nd quarter valued at $56,000. Finally, Geode Capital Management LLC raised its holdings in shares of MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after purchasing an additional 35,821 shares during the last quarter. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.